Proactive London's Andrew Scott speaks to Ergomed PLC's (LON:ERGO) chief financial officer Richard Barfield and head of clinical development Dr Gordana Tonkovic.
The firm's involved in a study at the Papa Giovanni XXIII Hospital in Bergamo, in Italy where the siltuximab antibody is being trialled in the treatment of patients with serious respiratory complications caused by COVID-19.
Ergomed's also had its results out this morning for 2019 which revealed £68.3mln of revenue for the twelve months ended 31 December, up 26.1%.